PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 171 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $390,506 | -5.9% | 11,270 | -21.4% | 0.00% | 0.0% |
| Q1 2024 | $415,001 | +37.7% | 14,345 | +9.2% | 0.00% | 0.0% |
| Q4 2023 | $301,276 | +61.5% | 13,139 | +17.5% | 0.00% | 0.0% |
| Q3 2023 | $186,516 | -37.2% | 11,182 | +4.0% | 0.00% | 0.0% |
| Q2 2023 | $297,052 | +45.3% | 10,755 | +21.0% | 0.00% | 0.0% |
| Q1 2023 | $204,378 | -35.5% | 8,886 | -33.7% | 0.00% | 0.0% |
| Q1 2022 | $317,000 | -43.8% | 13,399 | -18.7% | 0.00% | 0.0% |
| Q4 2021 | $564,000 | +100.0% | 16,489 | +3.8% | 0.00% | 0.0% |
| Q3 2021 | $282,000 | -66.3% | 15,892 | -14.7% | 0.00% | -50.0% |
| Q2 2021 | $836,000 | +110.1% | 18,621 | +21.2% | 0.00% | +100.0% |
| Q1 2021 | $398,000 | +53.1% | 15,367 | +19.4% | 0.00% | 0.0% |
| Q4 2020 | $260,000 | – | 12,875 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
| Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
| ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
| Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
| Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
| BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
| RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
| Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
| 683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
| Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |